Application US20200330425

LOZENGE FOR IMPROVED DELIVERY OF CANNABINOIDS
[+] Show Details

US20200330425

1-137. (canceled) (0)

138. A lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising: (15) (2)

i) a mucosal delivery enhancing component comprising one or more cannabinoids, an agent with hydrophobic interacting properties and one or more solid particles, the agent with hydrophobic interacting properties forming an encapsulation of the one or more cannabinoids, the encapsulation being reversibly associated with the one or more solid particles; and

ii) an extragranular component blended with the mucosal delivery enhancing component comprising one or more extragranular sugar alcohols.

139. The lozenge composition according to claim 138, wherein the one or more extragranular sugar alcohols are present in an amount of more than 50% by weight of the lozenge composition. (0)

140. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises one or more emulsifiers and one or more oil carriers. (0)

141. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises one or more emulsifiers and one or more solvents. (0)

142. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises one or more emulsifiers. (2) (0)

145. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises an oil carrier. (0)

146. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises a cannabinoid oil extract. (0)

147. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises one or more solvents. (1) (0)

149. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises one or more solubilizers. (1) (0)

151. The lozenge composition according to claim 138, wherein the agent with hydrophobic interacting properties comprises one or more cyclodextrins. (0)

152. The lozenge composition according to claim 138, wherein the weight ratio of the mucosal delivery enhancing component relative to the one or more extragranular sugar alcohols is from 1:30 to 1:2. (0)

153. The lozenge composition according to claim 138, wherein the mucosal delivery enhancing component further comprises one or more terpenes. (1) (0)

155. The lozenge composition according to claim 138, wherein the weight ratio of the one or more cannabinoids relative to the one or more solid particles is from 1:30 to 1:1. (0)

156. The lozenge composition according to claim 138, wherein the mucosal delivery enhancing component is present in an amount of 5 to 50% by weight of the lozenge composition. (0)

157. The lozenge composition according to claim 138, wherein the one or more solid particles is selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof. (0)

158. The lozenge composition according to claim 138, wherein the one or more solid particles is selected from the group consisting of xylitol, lactitol, sorbitol, maltitol, erythritol, isomalt and mannitol, and mixtures and combinations thereof. (0)

159. A lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising: (0) (2)

160. A lozenge composition for improved delivery of cannabinoids to mucosal surfaces comprising: (0) (2)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Application US20200330425

LOZENGE FOR IMPROVED DELIVERY OF CANNABINOIDS

Patent Matrix® Search